Squamous Cell Carcinoma (SCC) in Situ on the Lip
Dermatology Association of Tallahassee
Armand B. Cognetta Jr., M.D.
Earl Stoddard M.D.
Molly Warthan M.D.
Jerry Edwards REMT-P, HT (ASCP)cm
January 28, 2011
Dermatology Associates is a seven-person dermatology group with two Mohs surgeons, a fellow, an in-house plastic surgeon, and a dermatopathologist. We care for patients referred to us from about a 100-mile radius by dermatologists in lower Alabama, South Georgia, and the Florida Panhandle, as well as our own dermatologists and local and regional physicians.
Many of our patients have multiple cancers at the time of referral for Mohs Micrographic surgery. Depending on the location, size, depth, and aggressiveness of the individual tumor, and factoring in the patient’s age, health status, coagulation status, and what we term frailty index, we discuss Mohs surgery versus superficial radiation therapy (SRT) as part of the informed consent in patients over the age of 65. During this discussion of radiation, we offer treatment in our office of the SRT-100 or referral to local radiation oncologist. Approximately 10% of patients over the age of 65 referred for Mohs choose SRT. We have been providing this option for 25+ years and recently calculated our ten-year cure rates which compare very favorably to Mohs Micrographic surgery.
The patient is a 78 year old female who presented with a subtle crusty lesion on the right upper lip. She has a history of asthma and hypertension. She was referred to us for Mohs Micrographic surgery, but she wishes to avoid surgery if possible. She has had multiple skin cancers in the past.
The lesion on the right upper lip was biopsied and found to be an Squamous Cell Carcinoma (SCC) in situ that was amenable to SRT. The options of Mohs surgery or SRT were discussed with the patient. The patient opted for superficial radiation therapy for this lesion.
The clinical lesion was identified and circled. Then an 8-10 mm border was drawn around this.
The patient tolerated the treatment with no side effects. The patient returned 2 weeks post op with a good erythematous reaction from the SRT treatment. This should give her a good chance of cure.
Comment: The patient could have benefited from further fractionation for cosmesis (i.e) 300 cGy x15 or 250cGy x20, but due to her age and frailty this fractionation schedule worked well. The patient passed away 8 months after the treatment was finished from other causes.
The Benefits of SRT
Along with eliminating the risks for post-surgical infections and complications, the SRT-100™ provides patients and physicians with a safe and effective treatment option that offers many benefits, including:
- 95%+ cure rates that rival surgery
- No anesthesia, cutting, bleeding, stitching or pain
- No downtime or lifestyle restrictions
- Super cosmesis, no unsightly scarring
- No need for post-treatment reconstructive surgeries